Mapping Disease Pathways for Biliary Atresia (BA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03273049 |
|
Recruitment Status :
Recruiting
First Posted : September 6, 2017
Last Update Posted : December 5, 2023
|
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Submitted Date | September 1, 2017 | ||||||||
| First Posted Date | September 6, 2017 | ||||||||
| Last Update Posted Date | December 5, 2023 | ||||||||
| Actual Study Start Date | July 21, 2016 | ||||||||
| Estimated Primary Completion Date | December 21, 2025 (Final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures |
Genomic pathways of BA [ Time Frame: up to two years ] Main project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA.
|
||||||||
| Original Primary Outcome Measures | Same as current | ||||||||
| Change History | |||||||||
| Current Secondary Outcome Measures |
Predisposition of BA [ Time Frame: upwards of four years to achieve this outcome measure ] determine whether candidate genes and related pathways which predispose to BA, also predispose to laterality defects affecting the liver and other organs.
|
||||||||
| Original Secondary Outcome Measures | Same as current | ||||||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
| Descriptive Information | |||||||||
| Brief Title | Mapping Disease Pathways for Biliary Atresia | ||||||||
| Official Title | Coordinating Center- Mapping Disease Pathways for Biliary Atresia | ||||||||
| Brief Summary | This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children. | ||||||||
| Detailed Description | Characterized by failure to drain bile from the liver due to atretic extrahepatic bile ducts, BA is corrected in less than half of all affected children with surgical reconstruction. The remainder progress to cirrhosis and require liver transplantation. Because bile duct loss can be accompanied by other birth defects such as laterality defects of the gut and cardiovascular systems, the disease has been categorized into the more common 'isolated' variety presumably due to a perinatal viral cholangitis, and the 'syndromic' variety, due to genetic factors. Mechanistic differences implied by this categorization have not been demonstrated conclusively. In contrast, three susceptibility genes identified in predominantly 'isolated" BA cases, and the presence of abnormal cilia which are known to predispose to laterality defects, in both isolated and syndromic forms of BA suggest that in addition to environmental influences, genetic susceptibility is important in both forms of BA. This view is reinforced by our preliminary work which shows that knockdown of a novel BA susceptibility gene causes both biliary dysgenesis and laterality defects in animal models. This finding also suggests that common birth defects affecting the liver and other organs may originate from defects in the same genes. The project will combine candidate gene identification and replication with human DNA samples from 1100 BA subjects and their biological parents or siblings, if available, with validation using corresponding human BA liver tissue and zebrafish knockdown models. The project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA. The project will use the experimental and bioinformatics capabilities of the Universities of Pittsburgh and California (at San Diego) to analyze data and study human samples from the participating centers. Four of the world's largest pediatric liver transplant centers, the Children's Hospitals of Pittsburgh (CHP), King's College Hospital (KCH), London, UK, Birmingham Children's Hospital, UK (BCH), and the Hospital Sirio Libanes (HSL), Sao Paulo, Brazil will enroll biliary atresia subjects and their biological parents and/or siblings, if available. Information developed in this project will be the basis for designing novel management strategies to reduce the societal impact of this rare childhood disease. |
||||||||
| Study Type | Observational | ||||||||
| Study Design | Observational Model: Other Time Perspective: Prospective |
||||||||
| Target Follow-Up Duration | Not Provided | ||||||||
| Biospecimen | Retention: Samples With DNA Description: Samples with DNA: blood, saliva or liver tissue.
|
||||||||
| Sampling Method | Non-Probability Sample | ||||||||
| Study Population | Individuals who have had a liver transplantation due to a diagnosis of biliary atresia. | ||||||||
| Condition | Biliary Atresia | ||||||||
| Intervention | Not Provided | ||||||||
| Study Groups/Cohorts | Not Provided | ||||||||
| Publications * | Not Provided | ||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status | Recruiting | ||||||||
| Estimated Enrollment |
1100 | ||||||||
| Original Estimated Enrollment | Same as current | ||||||||
| Estimated Study Completion Date | July 21, 2027 | ||||||||
| Estimated Primary Completion Date | December 21, 2025 (Final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
| Sex/Gender |
|
||||||||
| Ages | Child, Adult, Older Adult | ||||||||
| Accepts Healthy Volunteers | No | ||||||||
| Contacts |
|
||||||||
| Listed Location Countries | United States | ||||||||
| Removed Location Countries | |||||||||
| Administrative Information | |||||||||
| NCT Number | NCT03273049 | ||||||||
| Other Study ID Numbers | STUDY19070273 1R01DK109365-01A1 ( U.S. NIH Grant/Contract ) |
||||||||
| Has Data Monitoring Committee | Yes | ||||||||
| U.S. FDA-regulated Product |
|
||||||||
| IPD Sharing Statement | Not Provided | ||||||||
| Current Responsible Party | Rakesh Sindhi, University of Pittsburgh | ||||||||
| Original Responsible Party | Same as current | ||||||||
| Current Study Sponsor | University of Pittsburgh | ||||||||
| Original Study Sponsor | Same as current | ||||||||
| Collaborators |
|
||||||||
| Investigators | Not Provided | ||||||||
| PRS Account | University of Pittsburgh | ||||||||
| Verification Date | December 2023 | ||||||||